Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 7Phase NA 4Phase 1 4Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 27INDUSTRY 9NIH 6NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Central Nervous System Neoplasms 8Multiple Myeloma 7Lung Neoplasms 7Leukemia, Myeloid, Acute 6Ovarian Neoplasms 5Uterine Cervical Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Leukemia 4Gliosarcoma 4Glioblastoma 4Burkitt Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Congenital Abnormalities 3Colorectal Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Radiation Injuries 2Pancreatic Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Neuroblastoma 2Myelodysplastic Syndromes 2Lymphoma 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2

Interventions

Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × NETWORK × Lymphoma, Large-Cell, Anaplastic × Clear all
NCT00939770 2020-06-09

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Children's Oncology Group

Phase 1/2 Completed
122 enrolled 24 charts 2 FDA
CNSLymphoid

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡